2026-10-29 11:37:15 UTC#536837newconfirmedpress release
Knight Therapeutics Inc. stock news
Knight Therapeutics Inc. stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire16 wire items
2026-10-06 11:56:14 UTC#419153duplicateconfirmedpress release
Knight Therapeutics receives ANVISA approval for NIKTIMVO in Brazil for cGVHD treatment
financial postimportance 0.30trust 0.90Knight Therapeutics Inc. +0.40NIKTIMVO +0.40ANVISA +0.20+1 entities
2026-10-06 11:55:27 UTC#419130newconfirmedpress release
Knight Therapeutics receives regulatory approval for Niktimvo in Brazil
2026-09-29 11:52:38 UTC#383852duplicateconfirmedpress release
Knight Therapeutics signs exclusive distribution deal with Kyowa Kirin for Poteligeo
financial postimportance 0.30trust 0.90Knight Therapeutics Inc. +0.30Kyowa Kirin Co., Ltd. +0.30Kyowa Kirin International +0.30+1 entities
2026-09-29 11:30:41 UTC#383672newconfirmednews
Knight Therapeutics secures exclusive rights to commercialize Poteligeo in Brazil, Mexico, Colombia, and Argentina
reutersimportance 0.40trust 0.80Knight Therapeutics Inc. +0.30Kyowa Kirin Co., Ltd. +0.30Poteligeo +0.30+1 entities
2026-09-29 11:30:00 UTC#383703duplicateconfirmednews
Knight Therapeutics Secures Exclusive Rights to Commercialize Poteligeo in Brazil, Mexico, Colombia, and Argentina
tradingviewimportance 0.30trust 0.80Knight Therapeutics Inc. +0.40Kyowa Kirin Co., Ltd. +0.30Mogamulizumab +0.40
2026-09-29 11:30:00 UTC#383702duplicateconfirmedpress release
Knight Therapeutics signs exclusive distribution deal with Kyowa Kirin for Poteligeo in Latin America
globenewswireimportance 0.30trust 1.00Knight Therapeutics Inc. +0.30Kyowa Kirin Co., Ltd. +0.30Mogamulizumab +0.30
2026-09-15 11:34:41 UTC#313344newconfirmedpress release
Knight Therapeutics files New Drug Submission for GEMTESA in Canada for overactive bladder treatment
2026-09-01 22:04:52 UTC#252239duplicateconfirmedpress release
Knight Therapeutics Receives Colombian Regulatory Approval for TAVALISSE
financial postimportance 0.30trust 0.90Knight Therapeutics Inc. +0.40INVIMA +0.30TAVALISSE +0.40+1 entities
2026-09-01 22:04:37 UTC#252204newconfirmednews
Knight Therapeutics receives Colombian regulatory approval for Tavalisse, launch expected 1H 2027
2026-08-27 22:02:22 UTC#231998duplicateconfirmedpress release
Knight Therapeutics files supplemental application with ANVISA for MINJUVI in Brazil
financial postimportance 0.30trust 0.90Knight Therapeutics Inc. +0.30ANVISA +0.30MINJUVI +0.30+2 entities
2026-08-27 22:01:40 UTC#231946newconfirmedpress release
Knight Therapeutics submits supplemental regulatory application for Minjuvi in Brazil
2026-08-20 11:34:39 UTC#200504newconfirmedpress release
Knight Therapeutics Launches WYNZORA Topical Psoriasis Cream in Canada
2026-08-06 10:34:07 UTC#136387newconfirmednews
Knight Therapeutics Reports Q2 2026 Revenue of $293M, Raises Full-Year Revenue Guidance to $540M-$560M
2026-08-06 10:34:00 UTC#136392duplicateconfirmednews
Knight Therapeutics raises 2026 revenue guidance to C$540M-C$560M
2026-07-30 10:33:26 UTC#100849newconfirmedpress release